Novo Nordisk tests grand acquisition in phase III trial

Pharmaceutical giant Novo Nordisk is testing a hormone test for diagnosing children with growth hormone deficiency in a phase III trial. Novo Nordisk bought the test back in 2018 for DKK 1.2bn as part of the firm's market race where it's competing with Ascendis Pharma on producing growth hormones.

Photo: Novo Nordisk Pharmatech/PR

Novo Nordisk has great expectations for the growth hormone market, where the pharmaceutical company is currently in competition with Danish biotech company Ascendis Pharma.

Around this time, Novo Nordisk is kicking off a phase III trial with hormone test Macrilen, which the company bought from Strongbridge Biopharma in a DKK 1.2bn (USD 191.9m) trade in 2018.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Britt Meelby Jensen wants to rebuild trust in Ambu

After a turbulent time for Ambu under Juan Jose Gonzalez’s reign, new chief executive appointee Britt Meelby Jensen aims to rebuild the trust in the medtech firm, which has downgraded its expectations seven times over the past three years.

Outgoing Ambu CEO commends colleagues

”A true privilege,” says Juan Jose Gonzalez, describing his time as CEO at Ambu, which came to an end with Thursday’s announcement that Britt Meelby Jensen would take over the role.

Further reading

Related articles

Latest news

See all jobs